Dr. Robert Kratzke
University of Washington School of Medicine, Seattle, WA - 1983
University of Wisconsin Hospital, Madison, WI - 1986
National Cancer Institute, Bethesda, MD (1988-1991)
Dr. Robert Kratzke is an associate professor of medicine in the division of hematology, oncology, and transplantation at the University of Minnesota located in Minneapolis. He also serves on the staff of the University of Minnesota’s Masonic Cancer Clinic as a medical oncologist. Dr. Kratzke received his medical degree in 1983 from the University of Washington School of Medicine in Seattle, Washington. He went on to complete his residency in internal medicine in 1986 at the University of Wisconsin Hospital located in Madison, Wisconsin. Dr. Kratzke stayed in Wisconsin through 1988 conducting research at the McArdle Laboratory for Cancer Research. A fellowship in medical oncology ensued at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) from 1988 to 1991 where Dr. Kratzke remained until 1994 carrying out further research. Prior to assuming his current position at the University of Minnesota, Dr. Kratzke was an assistant professor of medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland (1993-1994) and a staff physician at the Minneapolis VA Medical Center, Section of Hematology/Oncology (1994-2004).
Dr. Kratzke is board-certified in internal medicine and oncology and cites his areas of expertise as cancer, lung and esophageal cancer, and medical oncology. Dr. Kratzke is a member of the Thoracic Oncology Program at the University of Minnesota which promotes integrated care for all of its lung cancer and mesothelioma patients. This model of care involves a combination of surgery, medicine, and radiation aimed at achieving the best possible outcomes for patients.
Dr. Kratzke maintains several leadership roles in addition to the academic and clinical posts he holds at the University of Minnesota. He is vice chair of the Cancer and Leukemia Group B Respiratory Committee, he serves on the scientific advisory board of the Mesothelioma Applied Research Foundation (MARF), and is a member of the steering committee of the Big Ten Cancer Research Consortium (BTCRC)—a collaboration of the nation’s big ten cancer centers in which the institutions’ research leaders work together to take their groundbreaking science and transform it into clinical trials and treatment-changing models of cancer care.
Dr. Kratzke was the first individual to be honored with the prestigious John Skoglund Chair in Lung Cancer Research in 2004 at the University of Minnesota. He is a fellow of the American College of Surgeons (ACS), and a member of the American Society of Clinical Oncology (ASCO) and the American Federation for Medical Research (AFMR).
Clinical Research and Publications
Dr. Kratzke’s research interests are focused upon the development (preclinical and clinical) of innovative targets for the treatment of lung cancer and mesothelioma. In particular, he has investigated molecular abnormalities in mesothelioma and lung cancer and gene replacement therapy for mesothelioma.
Dr. Kratzke has authored or coauthored nearly 80 scientific articles. His work has been published in such journals as The New England Journal of Medicine, the Journal of Thoracic Oncology, Chest, Lung Cancer, the Journal of Clinical Oncology, The Journal of Thoracic and Cardiovascular Surgery, Translational Research, and The Annals of Thoracic Surgery, among others.
Dr. Kratzke’s most recent published articles focusing on mesothelioma include the following:
- Chen EZ, Jacobson BA, Patel MR, Okon AM, Li S, Xiong K, Vaidya AJ, Bitterman PB, Wagner CR, Kratzke RA. Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Invest New Drugs. 2014 Aug;32(4):598-603. Epub 2014 Apr 9.
- Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee H, Kratzke RA, Hoang CD. miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest. 2013 Nov;144(5):1632-43.
- Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr;7(4):755-9.
- Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun;76(3):393-6. Epub 2011 Dec 22.
- Raza A, Jacobson BA, Benoit A, Patel MR, Jay-Dixon J, Hiasa H, Ferguson DM, Kratzke RA. Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Invest New Drugs. 2012 Aug;30(4):1443-8. Epub 2011 Jul 26.
- Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct;5(10):1655-61.
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
University of Minnesota Medical School
University of Minnesota Medical Center
Big Ten Cancer Research Consortium